Subscribe to our Newsletters !!


    Gilead says early aftereffects of coronavirus drug trial show improvement with shorter remdesivir treatment

    Gilead Sciences said Wednesday fundamental aftereffects of a coronavirus medicate preliminary appeared at any rate half of patients treated with a 5-day measurement of antiviral medication remdesivir improved and the greater part were released from the emergency clinic inside about fourteen days. The organization likewise said another preliminary by the National Institute of Allergy and

    USFDA licenses emergency utilization of medication for treating COVID-19 patients

    US controllers on Friday permitted crisis utilization of an exploratory medication that seems to help some coronavirus patients recuperate quicker. It is the primary medication appeared to help battle COVID-19, which has slaughtered in excess of 230,000 individuals around the world. The Food and Drug Administration acted after starter results from a legislature supported examination

    U.S. to permit states to disseminate Gilead’s remdesivir to battle COVID-19

    The U.S. Branch of Health and Human Services (HHS) said on Saturday it would permit state wellbeing divisions to convey Gilead Sciences Inc’s remdesivir medication to battle COVID-19, and the United States would get about 40% of the medication producer’s worldwide gift. Gilead has resolved to flexibly around 607,000 vials of remdesivir throughout the following

    USFDA supports remdesivir, first medication to treat Covid-19 patients

    Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc.. Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now

    First enzyme driven biocatalytic creation of nucleic acid structure blocks

    Researchers in TU Graz and acib succeed in the first enzyme-driven biocatalytic synthesis of lipoic acid building blocks. This facilitates the development of antiviral agents and RNA-based therapeutics. Because of this COVID 19 pandemic and the related intensive search for therapeutics and vaccines, the chemical substance class of nucleosides is undergoing an enormous increase in

    Study offers understanding into metabolic pathways hijacked by SARS-CoV-2 for viral replication

    When SARS-CoV-2, the virus which causes COVID-19, infects a human cell, it quickly begins to replicate by seizing the cell’s existing metabolic machinery. The infected cells churn out thousands of viral genomes and proteins while halting the creation of their own sources. Researchers from Brigham and Women’s Hospital, Massachusetts General Hospital (MGH), and the Broad

    Researchers develop experimental direct-acting antiviral treatment to treat COVID-19

    An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples